• The problem is if you leave a single provirus, HIV can return. It’s different than needing to supply a functional form of a protein to enough cells that the body benefits. You can get high delivery rates with enough effort. But 100%?

    • By prolonging the anti retroviral therapy (with a regime containing a Reverse Transcriptase or Ingetrase Inhibitor) for a certain time after the CRISPR-Cas treatment should lead to the complete elimination of the viral DNA, comparable to PrEP in un-infected individuals.

    • If we ignore the costs, wouldn’t it be mostly a game of probabilities? If that’s the case it would be a matter of repeating the treatment often enough to reduce the probability of the virus returning to effectively 0.

      • If we ignore the costs, wouldn’t it be mostly a game of probabilities? If that’s the case it would be a matter of repeating the treatment often enough to reduce the probability of the virus returning to effectively 0.

        Yes, but a game of probabilities can mean that the management of a chronic condition becomes easier. It takes a certain amount of time for HIV to activate into AIDS. Modern management of HIV is a daily medication where dosage has a lot to do with what state you catch HIV in. With something like this, even if we cannot completely remove HIV from the person’s system, we may be able to reverse it to a state where it can be managed by the existing immune system and eliminated/cured, or at the very least can reduce how much of the medication one needs to be taking to keep things in check.

        To patients treatments like this might mean that in the future they may simply need to take a single pill or injection or undergo a minor procedure (such as an implant) much less often than once per day. This could greatly reduce the anxiety that one might experience around the question of whether they took their medication that day, or even remove the burden of having to refill/take a medication daily because it is instead an injection or procedure or implant.

        We are, of course, a LONG way from this being possible as human application of CRISPR is extremely limited and extremely expensive (we’ve cured sickle cell anemia in several humans now, with costs of the procedure in the millions) at this point in time, but it’s also amazing that we’ve even done that given how new CRISPR is.

      • My concern is it is a game of diminishing returns. But you’re right, repeated treatments would help and perhaps be necessary. This assumes that when the virus is latent there is no leakiness to that. If it spreads between cells a bit between treatments, then it could be a game of whack-a-mole.